155 related articles for article (PubMed ID: 38302240)
1. Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors.
Klapp V; Bloy N; Jiménez-Cortegana C; Buqué A; Petroni G
Methods Cell Biol; 2024; 181():197-212. PubMed ID: 38302240
[TBL] [Abstract][Full Text] [Related]
2. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
4. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
5. Many Ways to the Cell Cycle Exit after Inhibition of CDK4/6.
Macůrek L
Folia Biol (Praha); 2023; 69(5-6):194-196. PubMed ID: 38583181
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects.
Wekking D; Leoni VP; Lambertini M; Dessì M; Pretta A; Cadoni A; Atzori L; Scartozzi M; Solinas C
Cytokine Growth Factor Rev; 2024 Feb; 75():57-64. PubMed ID: 37838584
[TBL] [Abstract][Full Text] [Related]
7. Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment.
Liu J; Cheng M; Xu J; Liang Y; Yin B; Liang J
Immunol Invest; 2024 Apr; 53(3):437-449. PubMed ID: 38314676
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Klein ME; Kovatcheva M; Davis LE; Tap WD; Koff A
Cancer Cell; 2018 Jul; 34(1):9-20. PubMed ID: 29731395
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
12. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
14. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
16. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
17. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
18. Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
Romero-Pozuelo J; Figlia G; Kaya O; Martin-Villalba A; Teleman AA
Cell Rep; 2020 Apr; 31(2):107504. PubMed ID: 32294430
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
